title: Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
abstract: BACKGROUND
  This present study was designed to follow up 82 patients among 115 MDS patients registered in study ODK-0801 for 5 years, to analyze the relationship between the WT1 mRNA expression level and prognosis.
  
  
  OBJECTIVE
  This study aimed to investigate the clinical utility of WT1 mRNA expression levels.
  
  
  METHODS
  After study ODK-0801, we investigated the conditions of the same patients once a year, including any clinical and laboratory findings supporting the diagnosis, and treatment among the living patients.
  
  
  RESULTS
  When we assessed the survival time of 82 MDS patients by WT1 mRNA expression level, there were significant differences between the < 500 and ≥ 104 copies/μ g RNA groups and between the 500-104 and ≥ 104 copies/μ g RNA groups for BM levels (p < 0.01). Examination of the time of freedom from acute myeloid eukemia (AML) transformation indicated that a high WT1 mRNA expression level (> 104 copies/μ g RNA) was a strong prognostic factor for a short time to AML transformation.
  
  
  CONCLUSIONS
  The results indicate that the tumorigenesis of MDS is likely to originate at the stem cell level, suggesting that the WT1 mRNA level measurement in the BM is an effective prognostic marker in patients with MDS.
authors.affiliation: Department of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: Sumiko
authors.initials: S
authors.lastname: Kobayashi
authors.affiliation: Department of Haematology/Oncology, Transfusion and Haemapheresis Center, Kurashiki Central Hospital, Okayama, Japan.
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Ueda
authors.affiliation: Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Nannya
authors.affiliation: Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
authors.forename: Hirohiko
authors.initials: H
authors.lastname: Shibayama
authors.affiliation: Division of Hematology, Department of Medicine, Nippon Medical School, Tokyo, Japan.
authors.forename: Hideto
authors.initials: H
authors.lastname: Tamura
authors.affiliation: Division of Hematology, Department of Medicine, Nippon Medical School, Tokyo, Japan.|Department of Hematology, Shin-Yurigaoka General Hospital, Kanagawa, Japan.
authors.forename: Kiyoyuki
authors.initials: K
authors.lastname: Ogata
authors.affiliation: Department of Hematology, Fujita Health University School of Medicine, Aichi, Japan.
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Akatsuka
authors.affiliation: Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
authors.forename: Kensuke
authors.initials: K
authors.lastname: Usuki
authors.affiliation: Department of Hematology, Tokyo Medical University Hospital, Tokyo, Japan.
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Ito
authors.affiliation: Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
authors.forename: Masaya
authors.initials: M
authors.lastname: Okada
authors.affiliation: Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Suzuki
authors.affiliation: Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Hata
authors.affiliation: Department of Hemato-Oncology, Saitama International Medical Center, Saitama Medical University, Saitama, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Matsuda
authors.affiliation: Department of Laboratory Medicine, Kawasaki Medical School, Okayama, Japan.
authors.forename: Kaoru
authors.initials: K
authors.lastname: Tohyama
authors.affiliation: Information Management Office, Drug Safety Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
authors.forename: Keiji
authors.initials: K
authors.lastname: Kakumoto
authors.affiliation: Diagnostic Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Koga
authors.affiliation: Department of Hematology and Oncology, Dokkyo Medical University School of Medicine, Tochigi, Japan.
authors.forename: Kinuko
authors.initials: K
authors.lastname: Mitani
authors.affiliation: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.|National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
authors.forename: Tomoki
authors.initials: T
authors.lastname: Naoe
authors.affiliation: Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.
authors.forename: Haruo
authors.initials: H
authors.lastname: Sugiyama
authors.affiliation: Japanese Association of Medical Sciences, Tokyo, Japan.
authors.forename: Fumimaro
authors.initials: F
authors.lastname: Takaku
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D002869:Chromosome Aberrations; D005260:Female; D006801:Humans; D059785:Karyotype; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000235:genetics*; D025721:WT1 Proteins / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; D012333:RNA, Messenger; D025721:WT1 Proteins
keywords: IPSS; IPSS-R; Myelodysplastic syndromes; WPSS; Wilms tumor 1 mRNA expression level; bone marrow; follow-up study; peripheral blood